All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-09-09T12:42:03.000Z

Blinatumomab in adult patients with MRD negative B-ALL: Interim results from the ECOG-ACRIN E1910 trial

Sep 9, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL.

Results from the third interim efficacy analysis of the phase III ECOG-ACRIN E1910 trial (NCT02003222) evaluating blinatumomab in combination with standard consolidation chemotherapy in adult patients with BCR::ABL1 negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in measurable residual disease (MRD) negative remission were published in The New England Journal of Medicine by Litzow et al.1 

Key learnings

A total of 224 patients with BCR::ABL1-negative B-ALL in MRD negative remission were included in the analysis. 

  • 112 patients received blinatumomab + chemotherapy and 112 received only chemotherapy. 

  • Median age was 51 years and 50% were female. 

At a median follow-up of 43 months, the 3-year overall survival was significantly improved in the blinatumomab group vs chemotherapy alone group (85% vs 68%; hazard ratio for death, 0.41; 95% confidence interval [CI]: 0.23–0.73; p = 0.002). 

The 3-year relapse-free survival improved in the blinatumomab group vs chemotherapy alone group (80% vs 64%; hazard ratio for relapse or death, 0.53; 95% CI: 0.320.87). 

The incidence of treatment-related Grade ≥3 neurologic or psychiatric adverse events was higher in the blinatumomab group vs chemotherapy alone group (23% vs 5%; p < 0.001). 

The results suggest an overall survival benefit of the addition of blinatumomab to consolidation chemotherapy in adult patients with BCR::ABL1-negative B-ALL in MRD-negative remission; a longer international follow-up is needed to further confirm. 

  1. Litzow MR, Sun Z, Mattison RJ, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391(4):320-333. DOI: 10.1056/NEJMoa2312948 

Your opinion matters

I commit to reviewing the latest clinical data and recommendations for the optimal dosing of recombinant asparaginase in ALL to reduce and manage toxicities.
1 vote - 87 days left ...

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox